Evidence Based Digoxin Therapeutic Monitoring - A Lower and Narrower Therapeutic Range
PDF

Keywords

Digoxin
Drug monitoring
Pharmacokinetic
Pharmacodynamic
Digitalics
Heart fealure

How to Cite

1.
Benlmouden A, Billaud E. Evidence Based Digoxin Therapeutic Monitoring - A Lower and Narrower Therapeutic Range. Integr J Med Sci [Internet]. 2016Jan.30 [cited 2020Oct.30];3(1):22-5. Available from: https://mbmj.org/index.php/ijms/article/view/36

Abstract

Cardiac glycosides have been used for congestive heart failure and certain cardiac arrhythmias for more than 200 years. Despite the introduction of a variety of new classes of drugs for the management of heart failure, specifically angiotensin-converting enzyme (ACE) inhibitors, b-adrenergic antagonists (bblockers), and the aldosterone antagonist spironolactone, digoxin continues to have an important role in long-term outpatient management. However, a narrow margin exists between therapeutic and toxic doses of digoxin, resulting in a high incidence of digoxin toxicity in clinical practice.

A wide variety of placebo-controlled clinical trials have unequivocally shown that treatment with digoxin can improve symptoms, quality of life, and exercise tolerance in patients with mild, moderate, or severe heart failure. The clinical relevance of digoxin therapeutic monitoring is also proved but the SDC (Serum Digoxin Conentrations) required for optimal clinical efficacy and acceptable toxicity remains controversial. In the last years, international guidelines recommend 1.2 ng/mL as acceptable high level.

In this bibliographic synthesis, we aim to collect pertinent informations from MedLine database about exposure-effect relationship in order to assess the evidence level scientific of new digoxin therapeutic monitoring.

https://doi.org/10.15342/ijms.v3i1.87
PDF

References

Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004;109:2959–2964

The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal (2008) 29, 2388–2442

Winter ME. Basic clinical pharmacokinetics. Washington: Applied Therapeutics, Inc.; 1992. p. 147-72

Smith TW, Butler VP Jr, Haber E. Determination of therapeutic and toxic serum digoxin concentrations by immunoassay. N Engl J Med 1969;281: 1212- 1217

Lietuvos intensyviosios terapijos draugija „Ūminis širdies nepakankamumas intensyviojoje terapijoje“. (Society of intensive therapy of Lithuania: acute heart failure in the intensive therapy.) Kaunas: Informacijos technologijų mokymo centras; 2006. p. 63-74

Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: a stimulus for further research. Am Heart J 1997; 134: 3–12

Smith, T.W. Digitalis: Mechanisms of action and clinical use. New Engl. J. Med., 1988, 318:358-365

Nyberg, L., Andersson, K.E. and Bertlet, A., Bioavailability of digoxin from tablets. II. Radioimmunoassay and disposition pharmacokinetics of digoxin after intravenous administration. Acta Pharmacol. Suec., II (1974) 459-470

Aronson, J.K., Clinical pharmacokinetics of digoxin 1980. Clin. Pharmacokinet., 5 (1980) 137-149

Koren, G., Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin. Pharmacokinet., 13 (1987) 334-343

Eric J. Eichhorn and Mihai Gheorghiade. Digoxin. Progress in Cardiovascular Diseases, Vol. 44, No. 4, (January/February) 2002: pp 251-266

Walsh FM, Sode J. Significance of non-steady-state serum digoxin concentrations. Am J Clin Pathol 1975;63:446-50

Houin G, Royer-Morrot M-J, Lacarelle B. Suivi thérapeutique des digitaliques. In Suivi thérapeutique pharmacologique pour l’adaptation posologique des medicaments. Marquet P. 2004 Elsevier SAS, p :323-30

Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol 1992;69:97G–107G

SS. Rathore, JP. Curtis, Y Wang et al. Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure. JAMA 2003;289(7):871-878

A Ahmed, Michael W. Rich, T E. Love, D M. Lloyd-Jones, I B. Aban, W S. Colucci, K F. Adams Jr, C Hill, M Gheorghiade. Digoxin and Reduction in Mortality and Hospitalization in Heart Failure: A Comprehensive Post-Hoc Analysis of the DIG Trial. Eur Heart J. 2006 January; 27(2): 178–186

A Ahmed. Digoxin and Reduction in Mortality and Hospitalization in Geriatric Heart Failure: Importance of Low Doses and Low Serum Concentrations. J Gerontol A Biol Sci Med Sci. 2007; 62(3): 323–329

KF. Adams, JH Patterson, WA. Gattis, CM. O’Connor, CR. Lee, TA. Schwartz, M Gheorghiade Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trial; A Retrospective Analysis. Journal of the American College of Cardiology. Vol. 46, No. 3, 2005

Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946-53

Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265–70

Ordog GJ, Benaron S, Bhasin V, Wasserberger J, Balasubramanian S: Serum digoxin levels and mortality in 5,100 patients. Ann Emerg Med January 1987;16:32-39

EL. Eisenstein, S Yusuf, V Bindal, MG. Bourassa, A Horney, JF. Collins, DB. MARK. What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results From the DIG Trial. Journal of Cardiac Failure Vol. 12 No. 5 2006

HR Ochs, DJ. Greenblatt, G Bodem, JS. Harmatz. Dose-independent pharmacokinetics of digoxin in humans. American heart journal, 1978; Vol. 96, No 4:p507-11

Cusack B, Kelly J, O’Malley K, et al: Digoxin in the elderly: Pharmacokinetic consequences of old age. Clin Pharmacol Ther 1979;25:772-776

Ewy GA, Kapadia GG, Yao L, et al: Digoxin metabolism in the elderly. Circulation 1969; 39:449-453

Rowe JW, Andres R, Tobin JD, et al: The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 1976; 31:155-163

Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Goodman and Gilman’s the pharmacological basis of therapeutics, 9th edition. New York:McGraw-Hill; 1996. p. 809–38

A Dasgupta. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clinica Chimica Acta 377 (2007) 1–13

Terra SG, Washam JB, Dunham GD, Gattis WA. Therapeutic range of digoxin’s efficacy in heart failure: what is the evidence? Pharmacotherapy 1999;19:1123-6

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2016 Amine Benlmouden and Eliane Billaud